Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

Peter Hajek; Philip Tønnesen; Carmen Arteaga; Cristina Russ; Serena Tonstad

doi:10.1111/j.1360-0443.2009.02646.x

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

Peter Hajek, Philip Tønnesen, Carmen Arteaga, Cristina Russ, Serena Tonstad

Bachelor- og kandidatuddannelser

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

36 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Sep

Originalsprog	Engelsk
Tidsskrift	Addiction
Vol/bind	104
Udgave nummer	9
Sider (fra-til)	1597-602
Antal sider	6
ISSN	0965-2140
DOI	https://doi.org/10.1111/j.1360-0443.2009.02646.x
Status	Udgivet - 2009

Bibliografisk note

Keywords: Benzazepines; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors

Adgang til dokumentet

10.1111/j.1360-0443.2009.02646.x

Citationsformater

@article{73814fa0791611df928f000ea68e967b,

title = "Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment",

abstract = "AIM: While older behavioural and pharmacological approaches to preventing relapse to smoking show little efficacy, a recent randomized trial of an extended course of varenicline reported positive results. In this secondary analysis, trial data were examined to see whether smokers who manage to achieve abstinence only later in the original course of treatment are more likely to benefit from having the course extended. METHODS: A total of 1208 patients abstinent for at least the last week of 12 weeks' treatment with varenicline were randomized to 3 months continued varenicline or placebo. Overall, 44% of the 12-week abstainers were abstinent from the target quit date (TQD), while the rest stopped smoking later. We examined the relationship between quit pattern and the varenicline versus placebo difference in continuous abstinence rates at week 52 and contributions of baseline patient characteristics. RESULTS: With increasing delay in initial quitting, 12-month success rates declined. Participants who had their last cigarette at week 11 of open-label treatment had quit rates at 52 weeks of 5.7% compared with 54.9% in those who last smoked in week 1 [odds ratio (OR) 20.3 (6.3, 65.9); P < 0.0001]. Patients who failed to initiate abstinence in the first week benefited more from extended treatment than patients continuously abstinent from week 1 [OR 1.7 (1.2, 2.4); P = 0.0015 versus OR 1.1 (0.8, 1.5); P = 0.6995, respectively; with the interaction of the quit pattern with treatment effect reaching borderline significance (P = 0.0494)]. No other patient characteristics were related to treatment effect. CONCLUSIONS: Compared with smokers who quit smoking on their TQD, those who have an initial delay in achieving sustained abstinence have increased risk of relapse even several months later, and may be more likely to benefit from extended treatment with varenicline.",

author = "Peter Hajek and Philip T{\o}nnesen and Carmen Arteaga and Cristina Russ and Serena Tonstad",

note = "Keywords: Benzazepines; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors",

year = "2009",

doi = "10.1111/j.1360-0443.2009.02646.x",

language = "English",

volume = "104",

pages = "1597--602",

journal = "Addiction",

issn = "0965-2140",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

AU - Hajek, Peter

AU - Tønnesen, Philip

AU - Arteaga, Carmen

AU - Russ, Cristina

AU - Tonstad, Serena

N1 - Keywords: Benzazepines; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Recurrence; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Time Factors

PY - 2009

Y1 - 2009

N2 - AIM: While older behavioural and pharmacological approaches to preventing relapse to smoking show little efficacy, a recent randomized trial of an extended course of varenicline reported positive results. In this secondary analysis, trial data were examined to see whether smokers who manage to achieve abstinence only later in the original course of treatment are more likely to benefit from having the course extended. METHODS: A total of 1208 patients abstinent for at least the last week of 12 weeks' treatment with varenicline were randomized to 3 months continued varenicline or placebo. Overall, 44% of the 12-week abstainers were abstinent from the target quit date (TQD), while the rest stopped smoking later. We examined the relationship between quit pattern and the varenicline versus placebo difference in continuous abstinence rates at week 52 and contributions of baseline patient characteristics. RESULTS: With increasing delay in initial quitting, 12-month success rates declined. Participants who had their last cigarette at week 11 of open-label treatment had quit rates at 52 weeks of 5.7% compared with 54.9% in those who last smoked in week 1 [odds ratio (OR) 20.3 (6.3, 65.9); P < 0.0001]. Patients who failed to initiate abstinence in the first week benefited more from extended treatment than patients continuously abstinent from week 1 [OR 1.7 (1.2, 2.4); P = 0.0015 versus OR 1.1 (0.8, 1.5); P = 0.6995, respectively; with the interaction of the quit pattern with treatment effect reaching borderline significance (P = 0.0494)]. No other patient characteristics were related to treatment effect. CONCLUSIONS: Compared with smokers who quit smoking on their TQD, those who have an initial delay in achieving sustained abstinence have increased risk of relapse even several months later, and may be more likely to benefit from extended treatment with varenicline.

AB - AIM: While older behavioural and pharmacological approaches to preventing relapse to smoking show little efficacy, a recent randomized trial of an extended course of varenicline reported positive results. In this secondary analysis, trial data were examined to see whether smokers who manage to achieve abstinence only later in the original course of treatment are more likely to benefit from having the course extended. METHODS: A total of 1208 patients abstinent for at least the last week of 12 weeks' treatment with varenicline were randomized to 3 months continued varenicline or placebo. Overall, 44% of the 12-week abstainers were abstinent from the target quit date (TQD), while the rest stopped smoking later. We examined the relationship between quit pattern and the varenicline versus placebo difference in continuous abstinence rates at week 52 and contributions of baseline patient characteristics. RESULTS: With increasing delay in initial quitting, 12-month success rates declined. Participants who had their last cigarette at week 11 of open-label treatment had quit rates at 52 weeks of 5.7% compared with 54.9% in those who last smoked in week 1 [odds ratio (OR) 20.3 (6.3, 65.9); P < 0.0001]. Patients who failed to initiate abstinence in the first week benefited more from extended treatment than patients continuously abstinent from week 1 [OR 1.7 (1.2, 2.4); P = 0.0015 versus OR 1.1 (0.8, 1.5); P = 0.6995, respectively; with the interaction of the quit pattern with treatment effect reaching borderline significance (P = 0.0494)]. No other patient characteristics were related to treatment effect. CONCLUSIONS: Compared with smokers who quit smoking on their TQD, those who have an initial delay in achieving sustained abstinence have increased risk of relapse even several months later, and may be more likely to benefit from extended treatment with varenicline.

U2 - 10.1111/j.1360-0443.2009.02646.x

DO - 10.1111/j.1360-0443.2009.02646.x

M3 - Journal article

C2 - 19686530

VL - 104

SP - 1597

EP - 1602

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 9

ER -